Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?

**CURRENT STATUS:** UNDER REVIEW

Journal of Ovarian Research  •  BMC

Pim Laven  
Maastricht Universitair Medisch Centrum+

✉ pimlaven@gmail.com Corresponding Author  
ORCID: https://orcid.org/0000-0002-8679-5670

Roy Kruitwagen  
Maastricht Universitair Medisch Centrum+

Petra Zusterzeel  
Radboudumc

Brigitte Slangen  
Maastricht Universitair Medisch Centrum+

Toon van Gorp  
Katholieke Universiteit Leuven Universitair Ziekenhuizen Leuven

Jochem van der Pol  
Maastricht Universitair Medisch Centrum+

Sandrina Lambrechts  
Maastricht Universitair Medisch Centrum+

**DOI:**  
10.21203/rs.3.rs-24786/v1

**SUBJECT AREAS**  
*Sexual & Reproductive Medicine*

**KEYWORDS**  
*Ovarian cancer, Sentinel lymph node*
Abstract

Objective: Sentinel lymph node (SLN) detection in ovarian cancer is feasible when tracers are injected before the pathological ovary is resected. This study aims to investigate whether the SLN identification is also feasible in patients whose ovarian tumor has already been resected with injection of the tracer into the ovarian ligaments stumps, i.e. in the event that a frozen section confirms malignancy.

Methods: Patients who underwent laparotomy with frozen section confirming an ovarian malignancy, and those who underwent a second staging laparotomy after prior resection of a malignant ovarian mass, were included. Blue dye and a radioactive isotope were injected in the stumps of the ligamentum ovarium proprium and the ligamentum infundibulo-pelvicum. After an interval of at least 15-minutes, the sentinel node(s) were identified using either the gamma-probe and/or blue dye.

Results: A total of 11 patients were included in the study, the sentinel node (SLN) procedure was completed in all 11 patients. At least one SLN was identified in 3 patients, resulting in a rather low detection rate of 27.3%.

Conclusion: In this study we showed that SLN procedure after (previous) resection of the tumor seems inferior to detect sentinel nodes when compared to injection of the tracer in the ovarian ligaments before tumor resection.

Trial registration on clinical trials: NCT02540551 https://clinicaltrials.gov/ct2/show/NCT02540551

Introduction

The International Federation of Gynecology and Obstetrics recommends surgical staging in patients with clinical early-stage epithelial ovarian cancer (EOC) including pelvic and para-aortic lymphadenectomy to detect lymph node metastases. There is 14% (range 6.1–29.6%) chance of finding lymph node metastases, implicating pathological advanced stage disease with an indication for adjuvant chemotherapy \(^1\). The more lymph nodes are removed, the higher the likelihood of detecting metastases \(^2\). Although complete pelvic and para-aortic lymphadenectomy has been shown to detect up to 250 lymph nodes, radical lymphadenectomy has been associated with serious potential morbidity \(^3, 4, 5\) and there is therefore a great difference in the extent of lymph node
The concept of sentinel lymph node (SLN) surgery is widely used in different tumor types to assess whether the cancer has spread to the first lymph node in the lymph drainage pathway, called the SLN. The absence of cancer cells in the SLN is associated with a high probability that the cancer has not spread to other lymph nodes. The SLN technique has proven effective in the staging of various types of cancer, including breast cancer, malignant melanoma, and vulvar cancer (9, 10, 11). In these tumor types, the SLN technique has replaced the systematic performance of complete lymphadenectomy, reducing associated comorbidities such as lymphedema.

Several studies have described the feasibility of the SLN technique in patients with early-stage EOC (12-22). Most recent studies utilized a method in which a tracer is injected into the ovarian ligaments prior to tumor resection, with nearly all of these studies reporting very high detection rates (71–100%) of at least one SLN. If intraoperative pathologic examination of the frozen section confirms an ovarian malignancy, lymph node resection is performed. If the result of the frozen section shows a benign or borderline tumor, staging is not required and tracer injection prior to resection would have been unnecessary.

The main objective of this study was to investigate whether the SLN mapping technique is applicable to patients who have already undergone ovarian tumor resection. Using this technique, the tracer is injected into the stumps of the ovarian ligaments if either the result of a frozen section confirms malignancy, or definitive pathology confirms malignancy and a second surgical procedure is performed.

Materials And Methods
Patients
Patients who underwent laparotomy with frozen section for a pelvic mass suspicious for malignancy and those who underwent a second staging laparotomy after prior resection of a malignant ovarian mass at Maastricht University Medical Centre or Radboud University Medical Centre Nijmegen were included in this study. All patients provided fully informed written consent prior to study enrolment, and the study protocol was approved by the local ethics committee (approval number:
Patients were excluded if they had undergone previous vascular surgery of the aorta, caval vein, and/or iliac vessels; if they had undergone previous lymphadenectomy or lymph node sampling in the iliac or para-aortal region; if they had a history of malignant lymphoma or malignant tumor in the abdominal cavity; if they had experienced a previous allergic reaction to blue dye or human albumin; or if they were pregnant or lactating.

**SLN procedure**

Patients with high suspicion of a malignant ovarian tumor received general anesthesia. After median laparotomy, the ovarian tumor was removed and sent to the pathologist for frozen section analysis. In case of a benign or borderline result, SLN detection was not attempted. If the frozen section showed malignancy, four aliquots, each containing 0.2 ml patent blue dye and 0.15 ml (20 MBq) of radioactive 99mTc-nanocolloid (Nanocoll®; GE Healthcare, Eindhoven, the Netherlands), were injected into the dorsal and ventral sides of the remains of the ligamentum ovarium proprium and the ligamentum infundibulo-pelvicum (lateral side) just below the peritoneum (Fig. 1). After an interval of at least a 15 minutes, the retroperitoneal space of the pelvic and para-aortic regions was opened, and the presence of SLN(s) was examined using the gamma-probe and/or visually (blue dye). The surgeon recorded the number and location of the resected SLNs. Twelve locations were assessed: the upper and lower para-aortic regions, the upper and lower inter-aortocaval regions, the upper and lower para caval regions, the right and left common iliac regions, the right and left external iliac regions, and the right and left obturator fossa regions. After removal of identified SLNs, the location was re-examined with the gamma probe for the presence of other lymph nodes containing more than 10% of the activity in the SLN. After this procedure with or without detection of SLNs, the complete standard staging procedure was performed, including a comprehensive random sampling of other lymph nodes locations, hysterectomy, resection of the contralateral adnex and standard peritoneal biopsies.

The procedure performed in patients undergoing a second surgical staging procedure after resection of the ovarian malignancy was identical, starting with the injections of four aliquots of blue dye and radioactive tracer into the remnants of the ligaments.

**Histopathology**
SLNs and non-SLNs were examined separately. Non-SLNs were cut into single sections and stained with hematoxylin and eosin (H&E), according to the standard protocol for lymph node examination. SLNs were cut into 2 mm sections for H&E staining. H&E-negative SLNs in the first section were further cut into 0.5 mm sections and examined for the presence of micro metastases (0.2 mm). At each step, the sections were immunohistochemically stained with antibody to cytokeratin MNF-116.

Sample size calculation
In a previous study, the rate of detection of hotspot(s) following injection of radioactive tracers and a 15 min waiting period before resecting the adnexal mass was 100% \(^{(15)}\). Based on these results, a sample of 20 evaluable patients was considered large enough to determine whether identification of SLNs is feasible (detection rate of at least 50%) following a salpingo-oophorectomy and injection of tracers into the remnants of the ovarian ligaments. An interim analysis was planned after the evaluation of the first ten patients.

Results
The interim analysis was performed after the inclusion of eleven patients (the last two patients were included within one week). Patient characteristics are shown in Table 1. In three patients only, at least one SLN was identified (27%, CI 10–54%). Although the CI reached just above 50%, this low percentage prompted us to terminate the study prematurely.

None of the patients experienced any allergic or adverse reactions. The SLN procedure was performed on the left side in six patients (54.4%), on the right side in four patients (36.4%), and on both sides in one patient (9.1%). In eight patients, the SLN procedure was performed during the initial surgical procedure based on frozen section results indicative of malignancy. In the remaining three patients, a second surgical procedure was performed between 5 and 8 weeks after the original surgery.

SLN detection and location after injection
In three out of eleven patients SLN’s were identified with the \(\gamma\)-probe 15 min after the injection of the radioactive tracer (Table 2). In two of these patients, one SLN each was identified on the ipsilateral side, the para-aortic, and the paracaval region. In the remaining patient, two SLNs were found, one in the inter-aorto-caval region and the other close to the common iliac artery on the contralateral side.

No SLNs could be identified based on blue colorization. None of the SLNs were positive for metastasis.
Furthermore, none of these three patients had lymph node metastases in the non-SLNs, which were resected to complete the staging procedure. Of the eight patients lacking SLN, one had a lymph node metastasis in a non-SLN.

Discussion

Many studies have evaluated the feasibility of detecting SLNs by injecting tracer(s) into the mesovarium and/or ovarian ligaments. Tracer injection prior to tumor resection and examination by frozen sections resulted in very high detection rates (87.5-100%) of at least one SLN (12–22). The present study showed that injection of tracer into the remains of both ovarian ligaments after resection of the pathological adnex resulted in a low rate of SLN detection (3 out of 11 patients, 27%; CI 10–53%). Because of this disappointing result, the study was terminated prematurely.

To date, pre-operative techniques to predict ovarian malignancy have had only moderate results. One of the scoring systems to predict malignancy of adnexal masses is the risk of malignancy index (RMI), which has shown relatively poor performance, with a sensitivity of 78% and a specificity of 87% (23).

The rationale of our study was to inject the tracer after resection to prevent needless injection of (radioactive) tracer when subsequent frozen sections show benign or borderline pathology. Although the study population was small, the SLN detection rate was disappointingly low. To date, only one other study assessed the detection of SLNs following the injection of tracer into the remnants of the ovarian ligaments after the adnexa were resected, either during the same or a subsequent surgical procedure (21). The detection rate was 100% (10 out of 10 patients), being much higher than the 27% detection rate in the present study. They used a different type of tracer, indocyanine green, with the tracer being injected deep into the parametrium rather than superficially under the peritoneum (shown on a video which was provided as an appendix). The fact that in this group of patients the frequency of pelvic SLNs alone was remarkably high (88%), may suggest that in this situation the reliability could be lower due to either alteration of the lymphatic drainage after resection and/or technique of injection (deep rather than superficially under the peritoneum).

In a preliminary analysis of the first 31 patients enrolled in the SELLY trial, in 13 patients a secondary staging procedure was performed after an incidental diagnosis of ovarian cancer (24). They also used
ICG to identify the SLN(s) with a detection rate of 38%, compared to 88.9% when immediate staging was performed. If we combine their data with ours, the conclusion seems justified that the best results in identifying SLNs are obtained when the tracer is injected before the pathological ovary is resected.

Conclusion
The SLN mapping technique has shown high detection rates of 87.5–100% when tracers are injected before resecting the adnexa\(^{(22)}\). This technique therefore seems feasible and may prevent lymphadenectomy. The present study showed that the rate of SLN detection after prior tumor resection was disappointingly low (27%). Injection of (radioactive) tracer is therefore not indicated when subsequent frozen sections show benign or borderline pathology.

Based on these results, we support a standardized technique as proposed previously by Dell'Orto et al.\(^{(23)}\), of one injection in both the suspensory and the infundibulopelvic ligament of the ovary in all patients with a high suspicion of an ovarian mass limited to the ovary. The preferred tracer, although not yet clearly defined, should be indocyanine green, even though its use has been reported in only a limited number of cases. Recognizing that a number of centers will not have near-infrared fluorescent technology, the use of radiocolloid and blue dye is an acceptable alternative. After a waiting time of 10-15 minutes, the suspicious ovarian mass should be removed for frozen section analysis. If frozen section analysis confirms a malignancy, the staging procedure can start, including removal of the SLNs identified.

Using the proposed standardized technique, a protocol is being prepared with which we hope to launch an international multi-center collaborative study. This study will explore the accuracy and benefits of the SLN technique based on the injection of tracers in the ovarian ligaments in patients with clinical early-stage ovarian cancer.

List Of Abbreviations
SLN Sentinel lymph node
EOC Early stage ovarian cancer

Declarations
Ethics approval and consent to participate
All patients provided fully informed written consent prior to study enrolment, and the study protocol was approved by the local ethics committee at Maastricht university medical centre (approval number: NL53246.068.15).

Consent for publication

All authors consent for publication.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests

Funding

No funding was to be declared.

Author’s contributions:

PL wrote manuscript and collected data. RK and SL were principal investigators in Maastricht. PZ was principal investigator in Nijmegen. BS and TvG helped collecting patients for the study. JvP provided knowledge and helped with the radioactive tracers during surgery. All authors read and approved the final manuscript.

Acknowledgments

Not applicable

References

1. Kleppe M, Wang T, Van Gorp T, Slangen BF, Kruse AJ, Kruitwagen RF: Lymph node metastasis in stages I and II ovarian cancer: A review. Gynecol Oncol 2011;123:610-614.

2. Maggioni A, Benedetti Panici P, Dell’Anna T, et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer. 2006;95:699Y704

3. Harter P, Gnauert K, Hils R, et al. Pattern and clinical predictors of lymph node
metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007;17:1238Y1244.

4. Ditto A, Martinelli F, Reato C, et al. Systematic para-aortic and pelvic lymphadenectomy in early stage epithelial ovarian cancer: a prospective study. Ann Surg Oncol. 2012;19:3849Y3855.

5. Carnino F, Fuda G, Ciccone G, et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol. 1997;65:467Y472.

6. Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70:209-262.

7. Angioli R, Plotti F, Palaia I, et al. Update on lymphadenectomy in early and advanced ovarian cancer. Curr Opin Obstet Gynecol. 2008;20:34–39.

8. Di Re F, Baiocchi G. Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int J Gynecol Cancer. 2000;10: 435-442.

9. Gipponi, M., Bassetti, C., Canavese, G., Catturich, A., Di Somma, C., Vecchio, C., Nicolò, G., Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients. Journal of surgical oncology, 85(3):102-11.

10. Landi, G., Polverelli, M., Moscatelli, G., Morelli, R., Landi, C., Fiscelli, O., Erbazzi, A. Sentinel lymph node biopsy in patients with primary cutaneous melanoma: study of 455 cases. Journal of the european academy of dermatology and venereology. 14(1):35-45.

11. Levenback, C. F., Ali, S., Coleman, R. L., Gold, M. A., Fowler, J. M., Judson, P. L., ... & Leitao Jr, M. M. (2012). Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. Journal of Clinical Oncology, 30(31), 3786.

12. Vanneauville G, Mestas D, Le Bouedec G, et al. The lymphatic drainage of the human
ovary in vivo investigated by isotopic lymphography before and after the menopause. Surg and Radiol Anat 1991; 13 (3): 221-226.

13. Negishi H, Takeda M, Fujimoto T, et al. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol 2004; 94 (1): 161-166.

14. Nyberg RH, Korkola P, Mäenpää J. Ovarian sentinel node: is it feasible? Int J Gynecol Cancer 2011; 21 (3): 568-572.

15. Kleppe M, Brans B, van Gorp T, et al. The detection of sentinel nodes in ovarian cancer: a feasibility study. J Nucl Med. 2014;55:1799Y1804

16. Angelucci, M. Corrado, G. Vizza E. Laparoscopic indocyanine green sentinel lymph node mapping in early ovarian cancer. A pilot study and review of the literature. 2016 - Vol. 28 - N. 5 - Quarterly - ISSN 2385 - 0868

17. Hassanzadeh M, Farahabadi EH, et al. Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging. J Ovarian Res 2016; 9 (1): 55.

18. Nyberg RH, Korkola P, Mäenpää JU. Sentinel node and ovarian tumors: a series of 20 patients. Int J Gynecol Cancer 2017; 27 (4): 684-689.

19. Buda A, Passoni P, Corrado G, et al. Near-infrared fluorescence-guided sentinel node mapping of the ovary with indocyanine green in a minimally invasive setting: a feasible study. J Min Inv Gynecol 2017; 24(1): 165-170.

20. Speth SC, Kruitwagen, RF, Kleppe, M, et al. Comparison of intraoperative γ-probe imaging and postoperative SPECT/CT in detection of sentinel nodes related to the ovary. J Nucl Med 2017; 58 (2): 243-245.

21. Lago V, Bello P, Montero, B, et al. Clinical application of the sentinel lymph node technique in early ovarian cancer: a pilot study. Int J Gynecol Cancer 2019; 29 (2):
377-381.

22. Dell’Orto F, Laven P, Delle Marchette M, Lambrechts S, Kruitwagen R, Buda A. Feasibility of sentinel lymph node mapping of the ovary: a systematic review. Int J Gynecol Cancer 2019;29:1209-1215.

23. Meys EMJ, Kaijser J, Kruitwagen RFPM, Slangen BFM, Van Calster B, Aertgeerts B, Verbakel JY, Timmerman D, Van Gorp T. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis. Eur J Cancer 2016;58;17-29.

24. Uccella S, Nero C, Vizza E, Vargiu V, Corrado G, Bizzarri N, Ghezzi F, Cosentino F, Turco LC, Fagotti A, Cambia G. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). Am J Obstet Gynaecol 2019;221(4) 324.e1-324e10.

Tables
Table 1. Patient characteristics.
| Number of patients | 11 |
|--------------------|----|
| Median age         | 57 (44-79) |
| Pre- or post menopause |
| Post               | 7 (63.6%) |
| Pre                | 3 (27.3%) |
| Unknown            | 1 (9.1%) |
| Surgery            | 8 (72.7%) |
| Frozen section     | 3 (27.3%) |
| 2nd surgery        |          |
| Malignant          | 11 (100%) |
| FIGO Stage          |
| 1A                  | 7 (63.6%) |
| 1B                  | 4 (36.4%) |
| 1C                  | 0         |
| 2A                  | 0         |
| Tumor type         |
| Clear cell         | 5 (45.5%) |
| Serous             | 1 (9.1%)  |
| Mucinous           | 2 (18.2%) |
| Endometroid        | 3 (27.2%) |

Table 2 Sentinel nodes found

| Patient | Tumor side | Number of SLN | Histology during surgery | Location SLN | Histology after surgery | Metastases |
|---------|------------|---------------|--------------------------|--------------|-------------------------|------------|
| 1       | Right      | 1             | At least borderline      | Paracaval low right | Mucinous               |            |
| 2       | Left       | 1             | Mixed                    | Para aortal low left | Clear cell             |            |
| 3       | Left       | 2             | Clear cell               | Interaorta-caval, common iliac artery right | Clear cell         |            |

Figures
Figure 1

Location of injection of tracers. Tracers were injected on the ventral and dorsal sides of both ligament remains. Black arrow = remnant of infundibulo-pelvic ligament. Grey arrow = remnant of the ovarian ligament (proper ovarian ligament).